Table 5.
Ratio or difference between means (95% CIs) of fluconazole pharmacokinetic parameters after intravenous injection of fosfluconazole in subjects with normal, mild, moderate or severe renal impairment
| Parameter | AUC (µg-h ml−1) | Cmax (µg ml−1) | Tmax (h) | t1/2 (h) | MRT (h) |
|---|---|---|---|---|---|
| Mild | 112.8% | 107.7% | 0.8 | 2.2 | 3.6 |
| (89.5, 142.1) | (80.0, 145.0) | (−0.8, 2.5) | (−9.4, 13.8) | (−13.7, 20.9) | |
| Moderate | 240.6% | 130.2% | 0.3 | 43.3 | 62.9 |
| (128.2, 451.4) | (102.3, 165.8) | (−1.0, 1.6) | (−5.4, 92.0) | (−6.6, 132.4) | |
| Severe | 355.1% | 103.4% | 0.3 | 93.3 | 136.9 |
| (259.3, 486.3) | (81.8, 130.6) | (−0.8, 1.5) | (57.4, 129.1) | (85.6, 188.2) |
AUC, Area under the plasma concentration vs. time curve between time zero and infinity; Cmax, maximum observed plasma concentration; Tmax, first time to Cmax; t1/2, terminal elimination phase half-life; MRT, mean residence time. The ratio (Renal impairment group/Normal group) of the means for AUC and Cmax, and the difference (Renal impairment group − Normal group) between the means for all other parameters are presented.